All News

Experts explain the role and safety of Bayer's elinzanetant to treat vasomotor symptoms since its approval in October 2025.

SWAN data from 2066 women demonstrate that sleep disturbance has a greater independent effect on health-related quality of life than VMS alone, with the combination of both symptoms producing the most pronounced impact on physical functioning and energy—findings that support prioritizing sleep as a treatment target alongside vasomotor symptoms in menopausal care, according to Pauline M. Maki, PhD.

Research presented at ACOG suggests that gaps exist in sexual medicine education across Midwestern medical schools, potentially leading to underprepared graduates.

Eduardo Lara-Torre, MD, FACOG, emphasizes that pediatric and adolescent gynecology provides a critical bridge to ensure young patients do not lose access to care as they transition to adult providers.

Shared decision-making around nonhormonal VMS and sleep management requires moving through contraindications, patient preferences, and monitoring burdens together, with elinzanetant's (Lynkuet) dual receptor profile making it a particularly relevant option for women with both VMS and sleep disruption—and with follow-up at 2 to 3 months essential to evaluating response, according to Stephanie S. Faubion, MD, MBA, FACP, MSCP, IF.

Elle Kielar Grevstad, PhD, explains how a 2-MDM panel detected endometrial cancer in self-collected vaginal fluid with 96% sensitivity and 82% specificity, according to a marker reduction study published in Gynecologic Oncology.

Fiona C. Baker, PhD, explains how menopausal sleep disturbance differs from other forms of sleep disruption, citing the role of vasomotor symptoms, hormone changes, and an increased postmenopausal risk of sleep apnea in driving nighttime awakenings.

Originally approved in February 2020, levonorgestrel and ethinyl estradiol has now received FDA approval for an updated labeled strength expected to appear on the market in the fall of 2026.

Among SWAN participants, sleep disturbance was independently associated with lower HRQoL relating to role-physical, role-emotional, and energy/fatigue, with no change in these associations over time.

In part 2 of our discussion with Fiona Baker, PhD, she details how to interpret data from the NIRVANA study, which revealed reductions in wakefulness after sleep onset in the elinzanetant group vs placebo.

Elinzanetant produced a numerically greater reduction in PSG-measured WASO vs placebo across the 12-week NIRVANA trial, with the effect more pronounced at week 4 than week 12.

Backed by phase 3 data showing an overall success rate of 58.5% versus 60.2% for IV imipenem-cilastatin, tebipenem HBr has been approved by the FDA as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections in the US.

A post hoc analysis of the phase 2 NIRVANA trial presented at SLEEP 2026 found that elinzanetant reduced WASO versus placebo across in-lab PSG, home-based Sleepiz One+ monitoring, and patient-reported Sleep Diary.

Presented at SLEEP 2026, NIRVANA data show a consistent elinzanetant treatment signal across three sleep measurement modalities, extending earlier OASIS trial findings on patient-reported sleep outcomes in menopausal women.

The total treatment effect of elinzanetant on sleep disturbance relative to placebo was -4.92 (95% CI, -5.73 to -4.12), indicating a clinically meaningful reduction.

For the first time, ACOG has released its own version of vaccine recommendations, ones that differ from CDC recommendations.

Two neurokinin receptor antagonists are now available for vasomotor symptom (VMS)-related sleep disruption, with elinzanetant's (Lynkuet) NK1 and NK3 dual-receptor profile potentially offering more targeted sleep benefit than fezolinetant's (Veozah) NK3-selective mechanism—but effective management requires systematic screening for obstructive sleep apnea, restless leg syndrome, and primary insomnia before attributing sleep disruption to VMS alone

"Aside from the fact that mammograms have become unaffordable for the very women they were designed to protect, there is a big issue with them: They're not very effective, and they certainly aren’t preventive," writes Barbara Levy, MD, FACOG, FACS.

Mark Simon, MD, MMM, highlights the role of the OB hospitalist as a collaborative partner who can initiate rapid treatment for hypertensive crises in the hospital setting.

Published in Pregnancy, a single-center 20-year study of gastroschisis deliveries found that ultrasound-based bowel concern as a sole indication for delivery did not improve neonatal outcomes.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Using deep plasma proteomics rather than circulating tumor DNA, Certitude Breast addresses a known early-detection gap for breast cancer, particularly in women with dense breast tissue.

Susan Loeb-Zeitlin, MD, FACOG, breaks down the recently-updated ACOG guidance related to postmenopausal bleeding.

Aiming to address high maternal mortality rates and close the drug development gap for the 90% of pregnant patients using medications, SMFM's ongoing campaign highlights the vital role of perinatologists in managing high-risk pregnancies.

A cross-sectional analysis of 2024 national survey data published in JAMA Women's Health estimates that 17.9 million US women aged 45 to 64 are overdue for at least 1 recommended cancer screening.

Melissa Loseke, DO, highlighted evidence that testosterone therapy in women may improve energy, mood, cognition, and cardiometabolic markers beyond sexual function.

An updated consensus statement from the Society for Maternal-Fetal Medicine confirms that acetaminophen remains the safest first-line treatment for pain and fever during pregnancy.

The FDA has approved Wockhardt’s cefepime and zidebactam, a novel intravenous antibiotic that targets multiple penicillin-binding proteins to treat adults with complicated urinary tract infections.